Bereich
Infektiologie | Infektionsprävention | Reisemedizin
INFEKT · Dept. I
Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders
Tarr P, Telenti A, Ledergerber B, Rickenbach M, Darioli R, Bernasconi E, Vernazza P, Weber R, Battegay M, Hirschel B, Martinez R, Rotger M, Furrer H, Bleiber G, Taffé P, Swiss HIV Cohort Study. Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. The Journal of infectious diseases 2005; 191:1419-26.
01.05.2005Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders
01.05.2005The Journal of infectious diseases 2005; 191:1419-26
Tarr Philip E, Telenti Amalio, Ledergerber Bruno, Rickenbach Martin, Darioli Roger, Bernasconi Enos, Vernazza Pietro, Weber Rainer, Battegay Manuel, Hirschel Bernard, Martinez Raquel, Rotger Margalida, Furrer Hansjakob, Bleiber Gabriela, Taffé Patrick, Swiss HIV Cohort Study
Rezidiv einer medikamentös-toxischen Hepatitis
Hoffmann M, Marbet U, Hurni A, Bianchi L, Göldi H. Rezidiv einer medikamentös-toxischen Hepatitis. Swiss Med Forum 2005; 5:147-148.
01.04.2005Rezidiv einer medikamentös-toxischen Hepatitis
01.04.2005Swiss Med Forum 2005; 5:147-148
Hoffmann Matthias, Marbet Urs, Hurni Astrid, Bianchi Leonardo, Göldi Heiner
Impact of pregnancy and menopause on CD4 cell counts
van Benthem B, Vernazza P, Coutinho R, Prins M. Impact of pregnancy and menopause on CD4 cell counts. Journal of acquired immune deficiency syndromes (1999) 2005; 38 Suppl 1:S22.
01.03.2005Impact of pregnancy and menopause on CD4 cell counts
01.03.2005Journal of acquired immune deficiency syndromes (1999) 2005; 38 Suppl 1:S22
van Benthem Bikgit H B, Vernazza Pietro, Coutinho Roel A, Prins Maria
Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C
Broers B, Helbling B, François A, Schmid P, Chuard C, Hadengue A, Negro F, Swiss Association for the Study of the Liver (SASL 18). Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C. Journal of hepatology 2005; 42:323-8.
01.03.2005Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C
01.03.2005Journal of hepatology 2005; 42:323-8
Broers Barbara, Helbling Beat, François Anne, Schmid Patrick, Chuard Christian, Hadengue Antoine, Negro Francesco, Swiss Association for the Study of the Liver (SASL 18)
Interferon alpha-2a plus ribavirin 1,000/1,200 mg versus interferon alpha-2a plus ribavirin 600 mg for chronic hepatitis C infection in patients on opiate maintenance treatment: an open-label randomized multicenter trial
Huber M, Weber R, Oppliger R, Vernazza P, Schmid P, Schönbucher P, Bertisch B, Meili D, Renner E. Interferon alpha-2a plus ribavirin 1,000/1,200 mg versus interferon alpha-2a plus ribavirin 600 mg for chronic hepatitis C infection in patients on opiate maintenance treatment: an open-label randomized multicenter trial. Infection 2005; 33:25-9.
01.02.2005Interferon alpha-2a plus ribavirin 1,000/1,200 mg versus interferon alpha-2a plus ribavirin 600 mg for chronic hepatitis C infection in patients on opiate maintenance treatment: an open-label randomized multicenter trial
01.02.2005Infection 2005; 33:25-9
Huber M, Weber R, Oppliger R, Vernazza Pietro, Schmid P, Schönbucher P, Bertisch B, Meili D, Renner E L
Interferon alpha-2a Plus Ribavirin 1,000/1,200 mg versus Interferon alpha-2a Plus Ribavirin 600 mg for Chronic Hepatitis C Infection in Patients on Opiate Maintenance Treatment: An Open-Label Randomized Multicenter Trial
Schmid P. Interferon alpha-2a Plus Ribavirin 1,000/1,200 mg versus Interferon alpha-2a Plus Ribavirin 600 mg for Chronic Hepatitis C Infection in Patients on Opiate Maintenance Treatment: An Open-Label Randomized Multicenter Trial - M. Huber, R. Weber, R. Oppliger, P. Vernazza, P. Schmid, P. Schönbucher, B. Bertisch, D. Meili and E. L. Renner. Infection 2005; Volume 33:25-29.
01.02.2005Interferon alpha-2a Plus Ribavirin 1,000/1,200 mg versus Interferon alpha-2a Plus Ribavirin 600 mg for Chronic Hepatitis C Infection in Patients on Opiate Maintenance Treatment: An Open-Label Randomized Multicenter Trial
01.02.2005Infection 2005; Volume 33:25-29
Schmid Patrick
Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study
Young J, Battegay M, Vernazza P, Tarr P, Hirschel B, Bernasconi E, Furrer H, Weber R, Rickenbach M, Bucher H. Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study. Antiviral therapy 2005; 10:73-81.
01.01.2005Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study
01.01.2005Antiviral therapy 2005; 10:73-81
Young Jim, Battegay Manuel, Vernazza Pietro, Tarr Philip E, Hirschel Bernard, Bernasconi Enos, Furrer Hansjakob, Weber Rainer, Rickenbach Martin, Bucher Heiner C
Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study
Young J, Battegay M, Vernazza P, Tarr P, Hirschel B, Bernasconi E, Furrer H, Rickenbach M, Weber R, Bucher H. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study. Antiviral therapy 2005; 10:585-91.
01.01.2005Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study
01.01.2005Antiviral therapy 2005; 10:585-91
Young Jim, Battegay Manuel, Vernazza Pietro, Tarr Philip E, Hirschel Bernard, Bernasconi Enos, Furrer Hansjakob, Rickenbach Martin, Weber Rainer, Bucher Heiner C
HIV in semen: still more to be learned
Vernazza P. HIV in semen: still more to be learned. AIDS research and therapy 2005; 2:11.
01.01.2005HIV in semen: still more to be learned
01.01.2005AIDS research and therapy 2005; 2:11
Vernazza Pietro
Starting or changing therapy - a prospective study exploring antiretroviral decision-making
Fehr J, Spirig R, Jäger H, Vernazza P, Bregenzer T, Kiss A, Wagels T, Wolf E, Sendi P, Nicca D, Battegay M. Starting or changing therapy - a prospective study exploring antiretroviral decision-making. Infection 2005; 33:249-256.
01.01.2005Starting or changing therapy - a prospective study exploring antiretroviral decision-making
01.01.2005Infection 2005; 33:249-256
Fehr Jan, Spirig R, Jäger H, Vernazza Pietro, Bregenzer T, Kiss A, Wagels T, Wolf E, Sendi P, Nicca Dunja, Battegay Manuel
Adoptive Immunotherapy
Ludewig B, Hoffmann M. Adoptive Immunotherapy - Methods and Protocols. Totowa, New Jersey: Humana Press, 2004. ISBN 1-59259-862-5.
01.01.2005Adoptive Immunotherapy
01.01.2005Humana Press, ISBN 1-59259-862-5
Ludewig Burkhard, Hoffmann Matthias
A mathematical approach for optimising dendritic cell-based immunotherapy
Ludewig B, Bocharov G, Ford N, Hoffmann M. A mathematical approach for optimising dendritic cell-based immunotherapy. In: Adoptive Immunotherapy - Methods and Protocols. Totowa, New Jersey: Human Press, 2004. ISBN 1-59259-862-5. S. 19-34.
01.01.2005A mathematical approach for optimising dendritic cell-based immunotherapy
01.01.2005Human Press, ISBN 1-59259-862-5
Ludewig Burkhard, Bocharov Gennady, Ford Neville, Hoffmann Matthias
Predictive value of adherence in patients starting highly active antiretroviral treatment for HIV infection
Wagels T, Amiet R, Battegay M, Guex A, Opravil M, Vernazza P, Swiss HIV Cohort Study Group. Predictive value of adherence in patients starting highly active antiretroviral treatment for HIV infection. Swiss medical weekly : official journal of the Swiss Society of Infectious Diseases, the Swiss Society of Internal Medicine, the Swiss Society of Pneumology 2004; 134:678-80.
13.11.2004Predictive value of adherence in patients starting highly active antiretroviral treatment for HIV infection
13.11.2004Swiss medical weekly : official journal of the Swiss Society of Infectious Diseases, the Swiss Society of Internal Medicine, the Swiss Society of Pneumology 2004; 134:678-80
Wagels T, Amiet R, Battegay M, Guex A C, Opravil M, Vernazza Pietro, Swiss HIV Cohort Study Group
Long-term efficacy after switch from protease inhibitor-containing highly active antiretroviral therapy to abacavir, lamivudine, and zidovudine
Opravil M, Perrin L, Ledergerber B, Vernazza P, Blasko M, Bernasconi E, Calmy A, Furrer H, Chave J, Baumann D, Swiss HIV Cohort Study. Long-term efficacy after switch from protease inhibitor-containing highly active antiretroviral therapy to abacavir, lamivudine, and zidovudine. AIDS (London, England) 2004; 18:2213-5.
05.11.2004Long-term efficacy after switch from protease inhibitor-containing highly active antiretroviral therapy to abacavir, lamivudine, and zidovudine
05.11.2004AIDS (London, England) 2004; 18:2213-5
Opravil Milos, Perrin Luc, Ledergerber Bruno, Vernazza Pietro, Blasko Monika, Bernasconi Enos, Calmy Alexandra, Furrer Hansjakob, Chave Jean-Philippe, Baumann Doris, Swiss HIV Cohort Study
[Adherence and resistance]
Klimkait T, Vernazza P. [Adherence and resistance]. Therapeutische Umschau. Revue thérapeutique 2004; 61:631-4.
01.10.2004[Adherence and resistance]
01.10.2004Therapeutische Umschau. Revue thérapeutique 2004; 61:631-4
Klimkait T, Vernazza Pietro
[The Swiss HIV Cohort Study: from research to health care]
Vernazza P. [The Swiss HIV Cohort Study: from research to health care]. Therapeutische Umschau. Revue thérapeutique 2004; 61:591-2.
01.10.2004[The Swiss HIV Cohort Study: from research to health care]
01.10.2004Therapeutische Umschau. Revue thérapeutique 2004; 61:591-2
Vernazza Pietro
Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point
Trkola A, Günthard H, Bonhoeffer S, Hirschel B, Weber R, Bernasconi E, Vernazza P, Battegay M, Furrer H, Fagard C, Oxenius A, Leemann C, Kuster H, Swiss HIV Cohort Study. Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point. Blood 2004; 104:1784-92.
15.09.2004Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point
15.09.2004Blood 2004; 104:1784-92
Trkola Alexandra, Günthard Huldrych F, Bonhoeffer Sebastian, Hirschel Bernard, Weber Rainer, Bernasconi Enos, Vernazza Pietro, Battegay Manuel, Furrer Hansjakob, Fagard Catherine, Oxenius Annette, Leemann Christine, Kuster Herbert, Swiss HIV Cohort Study
Is unsafe sexual behaviour increasing among HIV-infected individuals?
Glass T, Bucher H, Battegay M, Hirschel B, Cavassini M, Weber R, Rickenbach M, Vernazza P, Young J, Swiss HIV Cohort Study. Is unsafe sexual behaviour increasing among HIV-infected individuals?. AIDS (London, England) 2004; 18:1707-14.
20.08.2004Is unsafe sexual behaviour increasing among HIV-infected individuals?
20.08.2004AIDS (London, England) 2004; 18:1707-14
Glass Tracy R, Bucher Heiner C, Battegay Manuel, Hirschel Bernard, Cavassini Matthias, Weber Rainer, Rickenbach Martin, Vernazza Pietro, Young Jim, Swiss HIV Cohort Study
Statin-induced immunomodulatory effects on human T cells in vivo
Fehr T, Kahlert C, Fierz W, Joller-Jemelka H, Riesen W, Rickli H, Wüthrich R, Ammann P. Statin-induced immunomodulatory effects on human T cells in vivo. Atherosclerosis 2004; 175:83-90.
01.07.2004Statin-induced immunomodulatory effects on human T cells in vivo
01.07.2004Atherosclerosis 2004; 175:83-90
Fehr Thomas, Kahlert Christian, Fierz Walter, Joller-Jemelka Helen I, Riesen Walter F, Rickli Hans, Wüthrich Rudolf P, Ammann Peter
Gynecomastia and potent antiretroviral therapy
Strub C, Kaufmann G, Flepp M, Egger M, Kahlert C, Cavassini M, Battegay M. Gynecomastia and potent antiretroviral therapy. AIDS (London, England) 2004; 18:1347-9.
18.06.2004Gynecomastia and potent antiretroviral therapy
18.06.2004AIDS (London, England) 2004; 18:1347-9
Strub Christoph, Kaufmann Gilbert R, Flepp Markus, Egger Martin, Kahlert Christian, Cavassini Matthias, Battegay Manuel